|1.||Mechoulam, Raphael: 19 articles (10/2015 - 04/2002)|
|2.||Mechoulam, R: 9 articles (04/2012 - 08/2000)|
|3.||Zuardi, Antonio Waldo: 8 articles (08/2015 - 09/2006)|
|4.||Di Marzo, Vincenzo: 7 articles (12/2015 - 09/2006)|
|5.||Whalley, Benjamin J: 7 articles (10/2015 - 02/2010)|
|6.||Crippa, José Alexandre S: 7 articles (08/2015 - 09/2006)|
|7.||Parker, Linda A: 7 articles (06/2015 - 04/2002)|
|8.||Mishima, Kenichi: 7 articles (09/2009 - 10/2004)|
|9.||Iwasaki, Katsunori: 7 articles (09/2009 - 10/2004)|
|10.||Fujiwara, Michihiro: 7 articles (09/2009 - 10/2004)|
08/01/2011 - "Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice."
02/01/2013 - "Sativex® (GW Pharmaceuticals PLC, Porton Down, UK; Laboratorios Almirall, SA, Barcelona, Spain), a cannabinoid oromucosal spray containing a 1:1 ratio of 9-δ-tetrahydrocannabinol and cannabidiol, has been licensed in Germany since July 2011 as add-on therapy for moderate-to-severe multiple sclerosis (MS) treatment-resistant spasticity symptoms. "
01/01/2015 - "The present study was designed to investigate the efficacy of a new formulation of alone, purified cannabidiol (CBD) (>98 %), the main non-psychotropic cannabinoid of Cannabis sativa, as a topical treatment in an experimental model of autoimmune encephalomyelitis (EAE), the most commonly used model for multiple sclerosis (MS). "
09/01/2015 - "The protective effects of cannabidiol (CBD) have been widely shown in preclinical models and have translated into medicines for the treatment of multiple sclerosis and epilepsy. "
11/01/2013 - "Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors."
01/01/1977 - "Cannabidiol was effective in blocking convulsions when given concurrently with, but not prior to delta9THC."
07/01/2013 - "The results of the present study showed a protective effect of cannabidiol in both PTZ and MES models of seizure. "
02/01/2010 - "Early studies suggested that cannabidiol (CBD) has anticonvulsant properties in animal models and reduced seizure frequency in limited human trials. "
05/01/2015 - "This report supports a role for cannabidiol in the treatment of malignant migrating partial seizures in infancy."
05/01/2015 - "We describe a now 10-month-old boy with malignant migrating partial seizures in infancy who made developmental gains and demonstrated sustained seizure reduction with the addition of cannabidiol to his antiepileptic regimen. "
08/01/2015 - "Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children. "
06/01/2015 - "Based on anecdotal reports and limited experience in an open-label trial, cannabidiol (CBD) has received tremendous attention as a potential treatment for pediatric epilepsy, especially Dravet syndrome. "
05/01/2015 - "Recent widespread interest in the nonpsychoactive component of the cannabis plant, cannabidiol, as a potential treatment for refractory devastating epilepsies has led to individual trials initiated by families or physicians in states that have legalized medical marijuana with anecdotal success. "
04/01/2015 - "Human studies are limited in number and quality, but suggest that cannabidiol has anticonvulsant effects in adult and infantile epilepsy and is well tolerated after prolonged administration. "
01/01/2015 - "The study was designed to investigate the effect of various concentrations of cannabidiol (CBD) in rats with chronic epilepsy. "
01/01/2011 - "Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study."
07/01/2008 - "In the present study, we investigated the effect of cannabidiol on intestinal motility in normal (control) mice and in mice with intestinal inflammation. "
04/01/2015 - "Cannabidiol (CBD) and its analogs: a review of their effects on inflammation."
01/01/2012 - "Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress."
09/01/2011 - "Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress."
11/01/2015 - "Sativex®, an equimolecular combination of Δ(9)-tetrahydrocannabinol-botanical drug substance (Δ(9)-THC-BDS) and cannabidiol-botanical drug substance (CBD-BDS), is a licensed medicine that may be prescribed for alleviating specific symptoms of multiple sclerosis (MS) such as spasticity and pain. "
12/14/2010 - "Cannabidiol, the most abundant nonpsychoactive constituent of Cannabis sativa (marijuana) plant, exerts anti-inflammatory effects in various disease models and alleviates pain and spasticity associated with multiple sclerosis in humans. "
09/01/2010 - "The nonpsychoactive cannabinoid, cannabidiol (CBD), has great potential for the treatment of chronic and 'breakthrough' pain that may occur in certain conditions like cancer. "
01/01/2013 - "However, other phytocannabinoids in combination, especially cannabidiol and β-caryophyllene, delivered by the oral route appear to be promising candidates for the treatment of chronic pain due to their high safety and low adverse effects profiles. "
06/01/2014 - "However, recent scientific data from studies with THC and cannabidiol combinations report the first clinical indication of cancer-related pain relief. "
|5.||tetrahydrocannabinol-cannabidiol combination (Sativex)
|8.||HU 211 (HU 210)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Drug Therapy (Chemotherapy)